Literature DB >> 9893112

Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

N Ismail1, B Becker, P Strzelczyk, E Ritz.   

Abstract

Recent epidemiologic data demonstrate a dramatic increase in the incidence of end-stage renal disease (ESRD) in patients with non-insulin-dependent diabetes mellitus (NIDDM), thus dispelling the mistaken belief that renal prognosis is benign in NIDDM. Currently, the leading cause of ESRD in the United States, Japan, and in most industrialized Europe is NIDDM, accounting for nearly 90% of all cases of diabetes. In addition to profound economic costs, patients with NIDDM and diabetic nephropathy have a dramatically increased morbidity and premature mortality. NIDDM-related nephropathy varies widely among racial and ethnic groups, genders and lifestyles; and gender may interact with race to affect the disease progression. While the course of insulin-dependent diabetes mellitus (IDDM) progresses through well-defined stages, the natural history of NIDDM is less well characterized. NIDDM patients with coronary heart disease have a higher urinary albumin excretion rate at the time of diagnosis and follow-up. This greater risk may also be associated with hypertension and hyperlipidemia, and genes involved in blood pressure are obvious candidate genes for diabetic nephropathy. Hyperglycemia appears to be an important factor in the development of proteinuria in NIDDM, but its role and the influence of diet are not yet clear. Tobacco smoking can also be deleterious to the diabetic patient, and is also associated with disease progression. Maintaining euglycemia, stopping smoking and controlling blood pressure may prevent or slow the progression of NIDDM-related nephropathy and reduce extrarenal injury. Treatment recommendations include early screening for hyperlipidemia, appropriate exercise and a healthy diet. Cornerstones of management should also include: (1) educating the medical community and more widely disseminating data supporting the value of early treatment of microalbuminuria; (2) developing a comprehensive, multidisciplinary team approach that involves physicians, nurses, diabetes educators and behavioral therapists; and (3) intensifying research in this field.

Entities:  

Mesh:

Year:  1999        PMID: 9893112     DOI: 10.1046/j.1523-1755.1999.00232.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  34 in total

1.  Establishment of a diabetic mouse model with progressive diabetic nephropathy.

Authors:  Akari Inada; Kojiro Nagai; Hidenori Arai; Jun-ichi Miyazaki; Keiko Nomura; Hiroshi Kanamori; Shinya Toyokuni; Yuichiro Yamada; Susan Bonner-Weir; Gordon C Weir; Atsushi Fukatsu; Yutaka Seino
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

2.  The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies.

Authors:  Sachin Yende; Tom van der Poll; Minjae Lee; David T Huang; Anne B Newman; Lan Kong; John A Kellum; Tamara B Harris; Doug Bauer; Suzanne Satterfield; Derek C Angus
Journal:  Thorax       Date:  2010-10       Impact factor: 9.139

Review 3.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

4.  Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions.

Authors:  Emmanuel I Agaba; Oladipo Adeniyi; Karen S Servilla; Dorothy J Vanderjagt; Robert H Glew; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 5.  Blood pressure lowering for the prevention and treatment of diabetic kidney disease.

Authors:  Merlin C Thomas; Robert C Atkins
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence.

Authors:  Daniel J Moore; Justin M Gregory; Yaa A Kumah-Crystal; Jill H Simmons
Journal:  Vasc Health Risk Manag       Date:  2009-11-23

7.  Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Authors:  Stefan Schäfer; Hans-Ludwig Schmidts; Markus Bleich; Andreas E Busch; Wolfgang Linz
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

8.  Study of an unusual advanced glycation end-product (AGE) derived from glyoxal using mass spectrometry.

Authors:  Andrea F Lopez-Clavijo; Carlos A Duque-Daza; Isolda Romero Canelon; Mark P Barrow; David Kilgour; Naila Rabbani; Paul J Thornalley; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-01-28       Impact factor: 3.109

9.  The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.

Authors:  Tao Jiang; Zheping Huang; Yifeng Lin; Zhigang Zhang; Deyu Fang; Donna D Zhang
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

10.  Diabetic nephropathy: prescription trends in tertiary care.

Authors:  D Padmini Devi; Jennifer George
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.